JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB145566

AG 825, ErbB2 inhibitor

Be the first to review this product! Submit a review

|

(0 Publication)

MW 397.5 Da, Purity >96%. Selective ErbB2 inhibitor (IC50 values are 0.15 and 19 μM at ErbB2 and ErbB1, respectively). Suppresses IL-6 induced STAT3 activation. Shows antiproliferative effects. Shows antitumor effects in vivo. .

View Alternative Names

1,8-cineole 2-exo-monooxygenase, 15-PGDH, 15-hydroxyprostaglandin dehydrogenase [NAD+], AI838772, AW493413, Albendazole monooxygenase, Albendazole sulfoxidase, Avian erythroblastic leukemia viral (v erb b) oncogene homolog, C erb B2/neu protein, CD340, CD340 antigen, CP2D6_HUMAN, CP33, CP34, CP3A4_HUMAN, CPC12, CPC8, CPC9, CPCJ, CPD6, CYP2C, CYP2C10, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIID6, CYPIIIA3, CYPIIIA4, Cell growth inhibiting protein 40, Cell proliferation inducing protein 61, CerbB2, Cholesterol 25-hydroxylase, Cytochrome P450 2D6, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450 family 2 subfamily D member 6, Cytochrome P450 family 2 subfamily D polypeptide 6, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450-DB1, Cytochrome P450-PCN1, Debrisoquine 4-hydroxylase, EGFR_HUMAN, ERBB, ERBB1, ERBB2_HUMAN, Epidermal growth factor receptor, Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog), Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian), Erb b2 receptor tyrosine kinase 2, ErbB-2 proto-oncogene, Errp, FLJ11090, GCN5 general control of amino acid synthesis 5 like 2, Glucocorticoid inducible P450, HER 2, HER 2/NEU, HER1, HLP, Herstatin, Hpgd, Human epidermal growth factor receptor 2, Hydroxyprostaglandin dehydrogenase 15 (NAD), JAK2_HUMAN, JTK 10, Janus Activating Kinase 2, Janus kinase 2, Janus kinase 2 (a protein tyrosine kinase), MGC104252, MGC112732, MGC126680, MLN 19, Metastatic lymph node gene 19 protein, Microsomal monooxygenase, NAD+ dependent 15 hydroxyprostaglandin dehydrogenase, NEU, NEU proto oncogene, NF 25, NGL, NISBD2, Neuro/glioblastoma derived oncogene homolog, Neuroblastoma/glioblastoma derived oncogene homolog, Nifedipine oxidase, OTTHUMP00000043260, OTTHUMP00000218960, OTTHUMP00000219016, OTTHUMP00000219018, Oncogen ERBB, P450 DB1, P450 III steroid inducible, P450 PB 1, P450 PCN1, P450, family III, P450C2C, P450C2D, P450C3, P450IIC19, P450IIC9, PGDH1, PGDH_HUMAN, PHOAR1, PIG61, Prostaglandin dehydrogenase 1, Proto-oncogene Neu, Proto-oncogene c-ErbB-1, Proto-oncogene c-ErbB-2, Quinine 3-monooxygenase, RP24-311F12.2, Receptor tyrosine-protein kinase ErbB-1, Receptor tyrosine-protein kinase erbB-2, SA7, SCAN1, SDR36C1, Short chain dehydrogenase/reductase family 36C member 1, Species antigen 7, THCYT3, TKR1, TYDP, TYDP1_HUMAN, Taurochenodeoxycholate 6-alpha-hydroxylase, Tyr-DNA phosphodiesterase 1, Tyrosine kinase-type cell surface receptor HER2, Tyrosine-protein kinase JAK2, Tyrosyl-DNA phosphodiesterase 1, Urogastrone, V erb b2 avian erythroblastic leukemia viral oncogene homolog 2, V erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog), V erb b2 avian erythroblastic leukemia viral oncoprotein 2, V erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog, V erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian), Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived-oncogene homolog, Wa5, Xenobiotic monooxygenase, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, erb-b2 receptor tyrosine kinase 1, flavoprotein-linked monooxygenase, kinase Jak2, mENA, p185erbB2, v-erb-b Avian erythroblastic leukemia viral oncogen homolog, wa2

1 Images
Chemical Structure - AG 825, ErbB2 inhibitor (AB145566)
  • Chemical Structure

Lab

Chemical Structure - AG 825, ErbB2 inhibitor (AB145566)

2D chemical structure image of ab145566, AG 825, ErbB2 inhibitor

Key facts

CAS number

149092-50-2

Purity

>96%

Form

Solid

form

Molecular weight

397.5 Da

Molecular formula

C<sub>1</sub><sub>9</sub>H<sub>1</sub><sub>5</sub>N<sub>3</sub>O<sub>3</sub>S<sub>2</sub>

PubChem

6091659

Nature

Synthetic

Solubility

Soluble in DMSO to 100 mM

Biochemical name

Tyrphostin AG 825

Biological description

Selective ErbB2 inhibitor (IC50 values are 0.15 and 19 μM at ErbB2 and ErbB1, respectively). Suppresses IL-6 induced STAT3 activation. Shows antiproliferative effects. Shows antitumor effects in vivo.

Canonical smiles

COC1=CC(=CC(=C1O)CSC2=NC3=CC=CC=C3S2)C=C(C#N)C(=O)N

Isomeric smiles

COC1=CC(=CC(=C1O)CSC2=NC3=CC=CC=C3S2)/C=C(\C#N)/C(=O)N

InChi

InChI=1S/C19H15N3O3S2/c1-25-15-8-11(6-12(9-20)18(21)24)7-13(17(15)23)10-26-19-22-14-4-2-3-5-16(14)27-19/h2-8,23H,10H2,1H3,(H2,21,24)/b12-6+

InChiKey

KXDONFLNGBQLTN-WUXMJOGZSA-N

IUPAC Name

(E)-3-[3-(1,3-benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxyphenyl]-2-cyanoprop-2-enamide

style
left-column
style
left-column

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The proteins JAK2 ErbB2 (also known as HER2) EGFR Cytochrome P450 3A4/CYP3A4 TDP1 CYP2D6 Cytochrome P450 2C8 2C9 2C19 and 2C12 as well as 15-PGDH each play distinct roles in cellular mechanisms. JAK2 with a mass of approximately 140 kDa functions as a non-receptor tyrosine kinase involved in cytokine receptor signaling and is expressed in various tissues including hematopoietic cells. ErbB2 or HER2 is a member of the ErbB family of receptor tyrosine kinases and is overexpressed in certain cancer cells. EGFR or epidermal growth factor receptor mediates cell growth and survival commonly localized to epithelial tissues. Cytochrome P450 enzymes like CYP3A4 and CYP2D6 are important for drug metabolism and are expressed in the liver. TDP1 is essential in repairing DNA damage. Finally 15-PGDH degrades prostaglandins participating in various bodily inflammation responses.
Biological function summary

Each of these proteins influences essential processes in the body. JAK2 participates in signal transduction for proliferation and differentiation via the JAK-STAT pathway. HER2 forms heterodimers with other ErbB family members facilitating cell signaling important for growth and differentiation. EGFR and HER2 create signal transduction complexes for similar functional roles in cellular proliferation. Within the liver CYP3A4 CYP2D6 and associated cytochrome P450 enzymes catalyze the oxidation of organic substances impacting drug pharmacokinetics. TDP1 operates in DNA single-strand break repair while 15-PGDH present in various tissues regulates prostaglandin levels and affects inflammation.

Pathways

ErbB2 and EGFR are central to the PI3K/AKT and RAS/RAF/MEK/ERK pathways both important for controlling cell division and survival. JAK2 is integral to the JAK-STAT pathway which impacts immune response and hematopoiesis. Cytochrome P450 enzymes like CYP3A4 and CYP2D6 are involved in the metabolic pathway impacting drug clearance and activation. These enzymes have interactions with diverse substrates affecting pathways related to hormone metabolism.

JAK2 mutations connect to myeloproliferative disorders such as polycythemia vera. Mutations or overexpression of HER2 are linked to breast cancer where HER2 inhibitors play a therapeutic role. EGFR mutations associate with non-small cell lung cancer influencing treatment approaches. In the context of liver functions variations in CYP3A4 and CYP2D6 can affect drug metabolism rates impacting efficacy and safety of medications. TDP1 mutations relate to neurological disorders such as spinocerebellar ataxia with axonal neuropathy. Each protein’s role in disease reflects its biological significance and potential therapeutic importance.
style
left-column
style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Complementary Products

Biochemicals

AB120503

BAPTA-AM, Ca2+ chelator

Immunocytochemistry/ Immunofluorescence - BAPTA-AM, Ca2+ chelator (AB120503)

  • 0
  • 0
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Biochemicals

AB120914

Xestospongin C, IP3 receptor antagonist

Chemical Structure - Xestospongin C, IP3 receptor antagonist (AB120914)

  • 0
  • 0
Primary Antibodies

AB192890

Anti-LC3B antibody [EPR18709] - Autophagosome Marker

BOND RX™ Validated|RabMAb|Recombinant|KO Validated|Lab Essentials|20ul selling size

Western blot - Anti-LC3B antibody [EPR18709] - Autophagosome Marker (AB192890)

  • 5
  • 19

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com